Proteomics: Fluorotechnics gets it right first time
02 December, 2003 by Iain ScottSydney start-up Fluorotechnics has signed a deal under which multinational Amersham Biosciences will exclusively supply and distribute its Deep Purple protein stain worldwide.
Proteomics: We have the technology
02 December, 2003 by Iain ScottDoing proteomics is expensive, relying on a suite of new and traditional technology with hefty price tags -- sample prep, mass specs, gel spot cutters, electrophoresis, and substantial IT hardware.
AGRF talks up genome project spin-off benefits
01 December, 2003 by Melissa TrudingerAs the Australian Genome Research Facility continues its drive to get AUD$6 million funding for the sequencing of the wallaby genome, the benefits of participating in a 'big science' project like this are becoming apparent.
Spina bifida gene identified in Melbourne study
11 November, 2003 by Melissa TrudingerA breakthrough in the understanding of congenital neural tube defect spina bifida has been made at Royal Melbourne Hospital with the discovery of the responsible gene in the curly-tail mouse model of the disease.
The $6 million wallaby: push continues for homegrown genome project
06 November, 2003 by Melissa TrudingerIn what Francis Collins has termed "an unprecedented offer," the US NIH's National Human Genome Research Institute has offered to share the cost of generating the sequence of the tammar wallaby genome despite going ahead with an American opossum species as the chosen marsupial for comparative genomics.
Getting value from grid computing
05 November, 2003 by David BraueGrowing interest in grid computing technologies will drive its rapid advancement as the technology grows from research darling to commercial reality, IBM's senior grid computing strategist, Rob Vrablik, predicted during a recent visit to Sydney.
NZ's Protemix takes the road less travelled
05 November, 2003 by Graeme O'NeillProf Garth Cooper, CEO of Auckland biopharmaceutical company Protemix, aims to make his company the first New Zealand biotech to take a discovered compound all the way to market.
VPAC goes commercial to target start-ups' IT needs
04 November, 2003 by David BraueSmall companies within Australia's growing life sciences industry are starting to compute like the big boys, thanks to a growing investment in the sector by companies keen to feed its hunger for high-performance computing (HPC) systems.
INTERVIEW: Getting up to Speed
17 October, 2003 by Melissa TrudingerThe thing about bioinformatics, according to Prof Terry Speed, is that it tends to attract people from a variety of disciplines, such as physicists with programming skills not interested in a career in defence, or mathematicians with a practical bent.
New plea: just $5m needed for homegrown genome project
14 October, 2003 by Melissa TrudingerAustralia risks being left out in the cold if it doesn't participate in efforts to sequence the marsupial genome, say leading genomics scientists who are trying to raise AUD$5 million in support of Australian participation.
Criminalise human cloning, says new group
09 October, 2003 by Melissa TrudingerA newly-formed international consortium of scientists and lawyers has launched a bid to have human reproductive cloning declared a crime against humanity.
New ARC scheme aims to create research networks
02 October, 2003 by Melissa TrudingerThe Australian Research Council has launched a new program aimed at encouraging the development of research networks, and fostering interdisciplinary research.
ComBio: Unravelling the subtleties of telomerase
02 October, 2003 by Melissa TrudingerThe telomeres are intriguing repetitive structures found on the chromosome tips, which are responsible for preventing the gradual erosion of the ends of the chromosomes.
ComBio 2003: Proteomics provides shortcut around antibody shortage
30 September, 2003 by Melissa TrudingerA predicted shortfall in global production capabilities of monoclonal antibodies for therapeutic purposes has led Queensland researchers to look at ways of boosting production of the antibodies in cell lines.
AGT broadens patent to include cancer, heart disease
29 September, 2003 by Graeme O'NeillAGT Biosciences has filed to broaden the patent on its SelS gene, already a prime suspect in type 2 diabetes and inflammatory diseases, to cover heart disease, cancer infertility and other disorders.
